Group 1 - Cerus Corporation (NASDAQ:CERS) is recognized as a promising investment opportunity, particularly due to its Intercept Fibrinogen Complex franchise, which is seen as an "underappreciated" growth engine by TD Cowen [1][2] - The recent partnership with Blood Centers of America (BCA) is expected to enhance the adoption and scalability of Cerus' products, significantly impacting profitability in the U.S. blood center market [1][3][4] - TD Cowen maintains a 'Buy' rating on Cerus Corporation with a price target of $5, indicating a potential upside of 143% from the current valuation [2] Group 2 - The purchasing agreement with BCA includes the complete INTERCEPT product offering, which features pathogen reduction technology aimed at increasing awareness and access to these technologies for new customers [3][4] - The COO of Cerus Corporation, Vivek Jayaraman, expressed optimism about the agreement's potential benefits for both BCA and Cerus, highlighting its positive implications for blood center membership [4]